Romosuzumab and Low Sclerostin Levels Underlie CV Risk New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS. https://t.co/tRGOXrm0Fk https://t.co/ebiRpCC81p